Research & Development

We have, since our inception, set our strategic focus on major therapeutic areas with substantial unmet medical needs.

10

In-house/co-developed novel antibodies

2020

plan to file first NDA

3

NDAs to file in next 18 months

18

Clinical trials ongoing

Multiple?

INDs in next 12-18 months

World Class R&D expertise
Cutting-edge antibody and cell therapy plassforms
Global clinical development capabilities
Global cGMP-compliant manufacturing capabillities
Collaborations and partnerships in China and globally
Deep China experience to drive commercial rollout
天津快乐10分高手预测